Eli Lilly's CEO, David Ricks, has reaffirmed the company's commitment to the Chinese market during a meeting with China's Commerce Minister Wang Wentao - stating Lilly's intention to increase investments and enhance R&D cooperation.

J&J has filed a lawsuit against a former employee - Andrew Brackhill - accusing him of illicitly downloading and taking thousands of sensitive documents with him to Pfizer.

To enhance its biologic manufacturing capabilities, Lonza is acquiring Genentech's Vacaville plant from Roche in a $1.2 billion deal. Once completed, Lonza will enhance capacity at the biologics facility, which is already one of the world’s largest, for clinical- commercial-stage manufacturing.

AstraZeneca has announced its intention to acquire Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer.

As election campaigns in the US begin to ramp up, Big Pharma continues to battle Biden’s plans to introduce negotiations for drug pricing.

With a notable shift in industry dynamics, increasing investments, and innovative breakthroughs, it appears we are witnessing signs of a significant resurgence.

A lawsuit led by a cystic fibrosis patient will see Vertex accused patent abuse and of violating patients’ human rights under the country’s constitution.

The company has received approval for Trikafta, a drug that can transform the lives of people with cystic fibrosis, but costs more than $300,000 per patient, per year.

Reflecting Singapore's growing status as a hub for Asia’s biopharmaceutical industry, Novartis has announced a $256 million expansion of its antibody manufacturing facility on the Malay peninsula.

2023 proved a tough year for biotech and pharmaceutical companies, and it seems that some companies are still having to make big decisions to stay in business.

London-based Relation Therapeutics has raised $60 million - including $35 million from the venture arm of Nvidia – to advance their technology in generating, analyzing and interpreting human data about the behaviour of genes, cells and tissues to identify new therapeutic targets and translate those into transformational medicines.

Eli Lilly and Amazon Pharmacy have announced a partnership set to enhance the delivery of Lilly’s prescription medications via a direct-to-consumer service, LillyDirect.

Recent FDA warning letters have highlighted data integrity issues at pharmaceutical manufacturing sites, particularly concerning microbiology and environmental monitoring.

Kasim Kutay, CEO of Novo Holdings, was recently interviewed by Bloomberg regarding the ongoing acquisition of Catalent, outlining Strategy 2030 and how they plan to reinvest cashflow and remain attractive to investors.

Adare Pharma Solutions, the global CDMO specializing in oral dosage forms, announced it will enhance its facility in Milan, Italy.

Tierra Biosciences has recently closed an $11 million Series A funding for its predictive AI protein engineering platform. The cash will be used to enhance capabilities in manufacturing proteins using predictive AI – across pharmaceutical, industrial and agricultural sectors.

Aspire Pharma, a UK-based company focusing on the development and enhancement of medicines, molecules and devices across a wide range of therapeutic areas, has completed the acquisition of Cenoté Pharma, a category specialist in carnitine deficiencies.

The FDA has granted breakthrough therapy status to the LSD-like substance MM120, developed by Mind Medicine Inc., to speed up the development and review for the treatment for generalized anxiety disorder (GAD).

Initially developed for type 2 diabetes - and its effectiveness in reducing food cravings and slowing stomach emptying - Wegovy has found fame in its ability to aid weight loss.

Looking forward in 2024, Fierce Pharma has published a report listing the drug patents that will expire in 2024, including for blockbusters from Bristol Myers Squibb and Biogen, plus medicines with prominent histories from Novo Nordisk, Astellas and Novartis.

Akari Therapeutics is merging with Peak Bio in an all-stock deal, creating a combined entity under the Akari Therapeutics Plc name. The merger will integrate Akari’s advanced clinical programs with Peak Bio's new drug candidates, focusing on cancer and rare diseases.